Abstract
Adequate drug delivery to tumors is hindered by barriers such as degradation and non-specific distribution. Nested incorporation of drug-containing nanoparticles within mesoporous silicon particles (MSVs), carriers rationally designed to enhance tumor transport, was hypothesized to result in pronounced and sustained antitumor efficacy. Paclitaxel (PTX)-containing poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL) polymer micelles were favorably loaded within MSVs, after which drug release was significantly delayed. Antitumor efficacy analyses in mice bearing MDA-MB-468 breast tumors demonstrated significant tumor growth suppression following a single administration. Results highlight effective chemotherapeutic shuttling and site-specific controlled release afforded by MSVs, potentially translating towards improvements in patient outcomes and morbidity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 245-252 |
| Number of pages | 8 |
| Journal | Cancer Letters |
| Volume | 334 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jul 1 2013 |
Keywords
- Cancer nanomedicine
- Mesoporous silicon particles
- Multistage drug delivery
- Paclitaxel
- Polymer micelles
ASJC Scopus subject areas
- Cancer Research
- Oncology
Fingerprint
Dive into the research topics of 'Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS